This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Glaxo Group Limited. Active years: 2012-2015.
Company Filing History:
Years Active: 2012-2015
Title: The Innovations of Stephen Anthony Burbidge
Introduction
Stephen Anthony Burbidge is a notable inventor based in Harlow, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and antigen binding proteins. With a total of 3 patents to his name, Burbidge's work focuses on addressing critical health issues related to elevated levels of β-amyloid.
Latest Patents
Burbidge's latest patents include innovative methods and compositions aimed at treating diseases characterized by elevated β-amyloid levels. One of his patents involves antibodies that bind human β-amyloid peptide, which can be used in methods of treating disorders associated with β-amyloid deposits. Another significant patent relates to antigen binding proteins that target β-amyloid peptide, specifically for conditions affecting the eye or optic nerve, such as age-related macular degeneration and glaucoma.
Career Highlights
Stephen Anthony Burbidge is currently associated with Glaxo Group Limited, where he continues to advance his research and development efforts. His work has the potential to impact the treatment of various diseases, particularly those related to neurodegeneration and vision impairment.
Collaborations
Burbidge has collaborated with notable colleagues, including Jonathan Henry Ellis and Susannah Karen Ford. These partnerships have likely contributed to the innovative nature of his research and the successful development of his patents.
Conclusion
Stephen Anthony Burbidge's contributions to biotechnology through his patents and research are noteworthy. His focus on addressing health challenges related to β-amyloid levels showcases the importance of innovation in the medical field.